Merus Labs International Inc. to Post Q1 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (TSE:MSL)

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – HC Wainwright issued their Q1 2024 EPS estimates for shares of Merus Labs International in a research note issued on Monday, April 15th. HC Wainwright analyst A. He forecasts that the specialty pharmaceutical company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. HC Wainwright also issued estimates for Merus Labs International’s Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.22) EPS.

Merus Labs International Price Performance

The stock has a 50 day moving average of C$1.65. Merus Labs International has a twelve month low of C$0.95 and a twelve month high of C$1.76.

Merus Labs International (TSE:MSL) (NASDAQ:MSLI) last released its quarterly earnings results on Wednesday, March 27th. The specialty pharmaceutical company reported C($0.06) earnings per share for the quarter, missing the consensus estimate of C($0.01) by C($0.05).

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.